Retatrutide & GLPs
Weight loss injections are game changers in the field of obesity and can be a major tool to help you get your health back.
Semaglutide (Wegovy, Ozempic), Tirzepatide (Mounjaro, Zepbound),
and the newest, RETATRUTIDE, are all now available at Dr. Chufo's Weight Loss and Wellness!
What is RETATRUTIDE? It is an injection that targets three chemical sensors and doubles the weight loss of the earlier GLP-1's, semaglutide and tirzepatide.
Lose 15, 40, 65, 100+ pounds and bonus health benefits of liver health,
joint pain, knee osteoarthritis, cardiac risks.
RETATRUTIDE is the current pinnacle that could change
obesity treatment dramatically forever.
Choose the option that works best for you:
Option 1: Have your medication vials shipped directly to your home with detailed instructions from Dr. Chufo so you can self-administer your injections.
Option 2: Visit our office each week, where Dr. Chufo will administer your injections, monitor your progress with a weekly weigh-in and measurements, and provide ongoing support.
Act now and realize the goal of your dream body!
The science backs retatrutide.
Read the published, peer-reviewed studies for yourself!
-
Obesity (without type 2 diabetes) – New England Journal of Medicine (2023)
-
Title: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
-
Authors: Jastreboff et al.
-
Key findings: Dose-dependent weight loss up to ~24% at 48 weeks with once-weekly retatrutide.
-
DOI: 10.1056/NEJMoa2301972
-
Related editorial: “Triple G Agonists — A Home Run for Obesity?” → https://www.nejm.org/doi/full/10.1056/NEJMe2307282
-
-
Type 2 diabetes – The Lancet (2023)
-
Title: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
-
Authors: Rosenstock et al.
-
Key findings: Meaningful HbA1c reductions and robust weight loss (up to ~17% at higher doses) vs. placebo and dulaglutide.
-
Link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
-
Abstract/alternate: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract
-
-
Body composition substudy (from the T2D Phase 2 trial) – The Lancet Diabetes & Endocrinology (2025)
-
Title: Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
-
Authors: Coskun et al.
-
Key findings: Significant reductions in total fat mass (proportion of lean mass loss similar to other obesity treatments).
-
Link: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/fulltext (or abstract page)
-